{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:19:28Z","timestamp":1790659168497,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["T32CA108456"],"award-info":[{"award-number":["T32CA108456"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","award":["1K01LM012100"],"award-info":[{"award-number":["1K01LM012100"]}],"id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["1R01CA158318-01A1"],"award-info":[{"award-number":["1R01CA158318-01A1"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","award":["P50CA159981-01A1"],"award-info":[{"award-number":["P50CA159981-01A1"]}],"id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01CA190174"],"award-info":[{"award-number":["P01CA190174"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ygyno.2017.03.509","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T02:00:42Z","timestamp":1491530442000},"page":"420-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer"],"prefix":"10.1016","volume":"145","author":[{"given":"J. Brian","family":"Szender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Papanicolau-Sengos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Miliotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Lugade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ygyno.2017.03.509_bb0005","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2017.03.509_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2017.03.509_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.03.509_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2017.03.509_bb0025","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2017.03.509_bb0030","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2017.03.509_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"issue":"Database issue","key":"10.1016\/j.ygyno.2017.03.509_bb0040","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ygyno.2017.03.509_bb0045","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.91.3.1004","article-title":"Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies","volume":"91","author":"Chen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.ygyno.2017.03.509_bb0050","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.ygyno.2017.03.509_bb0055","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2017.03.509_bb0060","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","article-title":"Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues","volume":"92","author":"Jungbluth","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.03.509_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-60327-811-9_2","article-title":"Autoantibodies against cancer antigens","volume":"520","author":"Gnjatic","year":"2009","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.03.509_bb0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"31","key":"10.1016\/j.ygyno.2017.03.509_bb0075","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2017.03.509_bb0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients","volume":"10","author":"Berinstein","year":"2012","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2017.03.509_bb0085","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.4049\/jimmunol.176.10.6340","article-title":"Influence of CD4+CD25+ regulatory T cells on low\/high-avidity CD4+ T cells following peptide vaccination","volume":"176","author":"Nishikawa","year":"2006","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.03.509_bb0090","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4049\/jimmunol.1000808","article-title":"Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity","volume":"186","author":"Tsuji","year":"2011","journal-title":"J. Immunol."},{"issue":"34","key":"10.1016\/j.ygyno.2017.03.509_bb0095","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2017.03.509_bb0100","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.ygyno.2017.03.509_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1054\/bjoc.2001.1974","article-title":"Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas","volume":"85","author":"Mashino","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2017.03.509_bb0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes","volume":"187","author":"Jager","year":"1998","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2017.03.509_bb0115","first-page":"4671","article-title":"Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade","volume":"61","author":"Kurashige","year":"2001","journal-title":"Cancer Res."},{"issue":"6230","key":"10.1016\/j.ygyno.2017.03.509_bb0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2017.03.509_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"7171","key":"10.1016\/j.ygyno.2017.03.509_bb0130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2017.03.509_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2017.03.509_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155189","article-title":"Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ygyno.2017.03.509_bb0145","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1007\/s13277-016-4812-9","article-title":"Potential biomarker for checkpoint blockade immunotherapy and treatment strategy","volume":"37","author":"Dong","year":"2016","journal-title":"Tumour Biol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817307266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T18:28:08Z","timestamp":1535912888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817307266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0090825817307266"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.509","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}